



# MARKET RELEASE

4 January 2018

## **Viralytics Limited**

### **TRADING HALT**

The securities of Viralytics Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Monday 8 January 2018 or when the announcement is released to the market.

Security Code:           VLA

Lux Wigneswaran

**PRINCIPAL ADVISER, LISTINGS COMPLIANCE (SYDNEY)**

**ASX RELEASE**  
**4 January 2018**

Luxmy Wigneswaran  
Principal Adviser, Listings Compliance (Sydney)  
ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

By email to: luxmy.wigneswaran@asx.com.au / tradinghaltssydney@asx.com.au

Dear Luxmy


**Viralytics Limited – Request for Trading Halt**

Pursuant to ASX Listing Rule 17.1, Viralytics Limited (**Viralytics**) (ABN 12 010 657 351) (ASX Code: VLA) requests a trading halt in respect of Viralytics ordinary shares from the commencement of trading today, 4 January 2018.

In accordance with Listing Rule 17.1, Viralytics advises that:

1. the trading halt is requested pending an announcement by Viralytics in relation to the outcome of a proposed capital raising;
2. Viralytics wishes the trading halt to remain in place until the earlier of such time as it makes an announcement to the market in relation to the outcome of the proposed capital raising and the commencement of trading on Monday, 8 January 2018; and
3. Viralytics is not aware of any reason why the trading halt should not be granted or of any information necessary to inform the market or ASX about the trading halt.

Signed for and on behalf of Viralytics:



Sarah Prince  
Company Secretary  
Viralytics Limited

**About Viralytics Ltd**

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. The company's lead investigational product, CAVATAK<sup>®</sup>, is currently being studied in clinical trials for the treatment of melanoma, as well as bladder and lung cancers. CAVATAK is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21) that preferentially binds to specific 'receptor' proteins highly expressed on multiple cancer types. CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells – a two-pronged mechanism of action known as oncolytic immunotherapy.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit [www.viralytics.com](http://www.viralytics.com).